{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:22Z","timestamp":1788783202540,"version":"build-2803163510"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor\u2013positive breast cancer (HR+ BC) represents the most common breast cancer subtype and is increasingly characterized by long-term survivorship complicated by substantial cardiometabolic and cardiovascular morbidity. Endocrine therapies, including aromatase inhibitors, selective estrogen receptor modulators and degraders, and ovarian suppression, remain central to disease control but promote metabolic dysfunction, vascular injury, and systemic inflammation, thereby increasing cardiovascular disease (CVD) risk and potentially contributing to endocrine resistance. These alterations are also associated with adverse changes in adipose tissue distribution, increased visceral fat accumulation, and dysregulated lipid metabolism, further amplifying cardiometabolic risk. Consequently, CVD has emerged as a leading cause of non-cancer mortality among breast cancer survivor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a comprehensive narrative review of mechanistic, preclinical, and clinical evidence evaluating the cardiometabolic and oncologic effects of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) in the context of breast cancer and cardio-oncology. Literature from experimental models, observational and real-world studies was synthesized to delineate the biological pathways through which SGLT2i may influence cardiovascular risk, metabolic health, and endocrine therapy resistance in HR + BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>SGLT2 inhibitors, originally developed as glucose-lowering agents, confer robust cardiovascular and renal protection that extends beyond glycemic control. Emerging evidence indicates that SGLT2i modulate key biological pathways relevant to HR+ BC survivorship, including insulin\u2013IGF-1 signaling, PI3K\u2013Akt\u2013mTOR and AMPK pathways, adipose tissue inflammation, hepatic steatosis, endothelial dysfunction, myocardial energetics, and systemic inflammatory tone. In addition, SGLT2i promote favorable adipose tissue remodeling, with preferential reduction in visceral adiposity and improvement in adipokine profiles, and induce lipid metabolism reprogramming characterized by enhanced fatty acid oxidation and reduced hepatic lipogenesis, contributing to improved cardiometabolic homeostasis. Observational and propensity-matched studies in oncology populations associate SGLT2i use with reduced incidence of heart failure, attenuation of cancer therapy\u2013related cardiac dysfunction, and improved cardiovascular outcomes, including in breast cancer survivors exposed to cardiotoxic therapies. Beyond cardiovascular protection, converging data suggest that SGLT2i may indirectly mitigate or delay resistance to endocrine therapy by suppressing hyperinsulinemia-driven growth signaling, remodeling adipokine and inflammatory networks, and altering tumor\u2013host metabolic interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2 inhibition represents a promising systems-level strategy at the intersection of cardio-oncology, metabolism, and endocrine resistance in HR+ breast cancer. By simultaneously targeting glucose homeostasis, adipose tissue dysfunction, and lipid metabolism, SGLT2i may improve both cardiovascular outcomes and long-term cancer control. Dedicated prospective trials are urgently needed to define their clinical role in breast cancer survivorship and precision cardio-oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08473-8","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:14:28Z","timestamp":1782152068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-5401","authenticated-orcid":false,"given":"Vincenzo","family":"Quagliariello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Bisceglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Arianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Inno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Cadeddu","family":"Dessalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Di Matola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"1","key":"8473_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-025-02181-3","volume":"10","author":"C Liu","year":"2025","unstructured":"Liu C, Sun L, Niu N, Hou P, Chen G, Wang H, et al. Molecular classification of hormone receptor-positive \/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies. Sig Transduct Target Ther. 2025, Mar, 26;10(1):97. https:\/\/doi.org\/10.1038\/s41392-025-02181-3. PMID: 40133264; PMCID: PMC11937365.","journal-title":"Sig Transduct Target Ther"},{"key":"8473_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.20517\/cdr.2024.169","volume":"8","author":"Cejalvo And\u00fajar","year":"2025","unstructured":"Cejalvo And\u00fajar, de la Pe\u00f1a FA, Margeli Vila M, Pascual J, Tolosa P, Pages C, et al. Optimizing therapeutic approaches for HR+\/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4\/6 inhibitor progression. Cancer Drug Resist. 2025, Jan, 22;8:5. https:\/\/doi.org\/10.20517\/cdr.2024.169. PMID: 39935426; PMCID: PMC11810462.","journal-title":"Cancer Drug Resist"},{"key":"8473_CR3","doi-asserted-by":"publisher","unstructured":"Vacharanukrauh P, Miller KJ, Alif SM, Grace F, Rahman MA. Heart failure related cardiotoxicity in breast cancer survivors: a scoping review. Cardio-Oncology. 2025, Dec, 29;12(1). https:\/\/doi.org\/10.1186\/s40959-025-00434-2. Epub ahead of print. PMID: 41457228.","DOI":"10.1186\/s40959-025-00434-2"},{"issue":"6","key":"8473_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/ijerph22060920","volume":"22","author":"MA Miles","year":"2025","unstructured":"Miles MA, Akinyele O, Ninson AA, Caviness-Ashe N, Means C, Anderson-Tolbert L, et al. A systematic review of cardiovascular health among cancer survivors. IJERPH. 2025, Jun, 10;22(6):920. https:\/\/doi.org\/10.3390\/ijerph22060920. PMID: 40566347; PMCID: PMC12193435.","journal-title":"IJERPH"},{"issue":"3","key":"8473_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/biom15030373","volume":"15","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis N, Nikolaou M, Krentz A. Cardiovascular\u2013endocrine\u2013metabolic Medicine: proposing a New clinical sub-specialty amid the cardiometabolic Pandemic. Biomolecules. 2025, Mar, 5;15(3):373. https:\/\/doi.org\/10.3390\/biom15030373. PMID: 40149908; PMCID: PMC11940337.","journal-title":"Biomolecules"},{"issue":"7","key":"8473_CR6","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/jnci\/djaf063","volume":"117","author":"Y Huang","year":"2025","unstructured":"Huang Y, Kwan ML, Heckbert SR, Smith NL, Othus M, Laurent CA, et al. Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors. JNCI: J Natl Cancer Inst. 2025, Jul, 1;117(7):1401\u201309. https:\/\/doi.org\/10.1093\/jnci\/djaf063. PMID: 40071691; PMCID: PMC12707390.","journal-title":"JNCI: J The Natl Cancer Inst"},{"issue":"25","key":"8473_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","volume":"81","author":"MS Usman","year":"2023","unstructured":"Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023, Jun, 27;81(25):2377\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.034. PMID: 37344038.","journal-title":"J Am Coll Cardiol"},{"key":"8473_CR8","doi-asserted-by":"publisher","unstructured":"Vart P. From kidney to Heart \u2014 and beyond \u2014 SGLT2 inhibitors in Chronic kidney disease. NEJM Evidence. 2025, Nov;4(11):EVIDe2500255. https:\/\/doi.org\/10.1056\/EVIDe2500255. Epub 2025 Oct 28. PMID: 41147821.","DOI":"10.1056\/EVIDe2500255"},{"issue":"21","key":"8473_CR9","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022, May, 26;386(21):2024\u201334. https:\/\/doi.org\/10.1056\/NEJMra2115011. PMID: 35613023.","journal-title":"N Engl J Med"},{"issue":"10","key":"8473_CR10","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.3390\/ijms26104780","volume":"26","author":"A Greco","year":"2025","unstructured":"Greco A, Canale ML, Quagliariello V, Oliva S, Tedeschi A, Inno A, et al. SGLT2 inhibitors in cancer patients: a Comprehensive review of clinical, Biochemical, and therapeutic Implications in cardio-oncology. IJMS. 2025, May, 16;26(10):4780. https:\/\/doi.org\/10.3390\/ijms26104780. PMID: 40429921; PMCID: PMC12112039.","journal-title":"IJMS"},{"issue":"1","key":"8473_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1186\/s12885-025-14280-z","volume":"25","author":"I Cheang","year":"2025","unstructured":"Cheang I, Gue Y, Wu MZ, Huang JY, Ren QW, Chen Z, et al. Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study. BMC Cancer. 2025, Jul, 1;25(1):1063. https:\/\/doi.org\/10.1186\/s12885-025-14280-z. PMID: 40597894; PMCID: PMC12210659.","journal-title":"BMC Cancer"},{"issue":"16","key":"8473_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/heartjnl-2020-317510","volume":"107","author":"AA Matthews","year":"2021","unstructured":"Matthews AA, Peacock Hinton S, Stanway S, Lyon AR, Smeeth L, Lund JL, et al. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart. 2021, Aug;107(16):1327\u201335. https:\/\/doi.org\/10.1136\/heartjnl-2020-317510. Epub 2020 Nov 11. PMID: 33177117; PMCID: PMC8327412.","journal-title":"Heart"},{"issue":"7","key":"8473_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction\u2013associated steatotic liver disease. N Engl J Med. 2025, Aug, 14;393(7):683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865. PMID: 40802944.","journal-title":"N Engl J Med"},{"issue":"2","key":"8473_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","volume":"72","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2023, Jul;72(2):372\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2022-327672. Epub ahead of print. PMID: 35879047.","journal-title":"Gut"},{"issue":"5","key":"8473_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14304\/SURYA.JPR.V1N5.4","volume":"1","author":"CN Miller","year":"2013","unstructured":"Miller CN, Della-Fera MA, Baile CA. The mediation of hepatic lipogenesis through estrogens. PDJ. 2013, May;1(5):27\u201338. PMID: 27904876; PMCID: PMC5125724. https:\/\/doi.org\/10.14304\/SURYA.JPR.V1N5.4.","journal-title":"PDJ"},{"key":"8473_CR16","doi-asserted-by":"publisher","unstructured":"Zhong Y, Huang Y, He J, Xie R, Li L. The association between visceral adiposity index and breast cancer in middle-aged and older US women: a cross-sectional analysis of NHANES 2009 to 2018. Med (Baltim). 2025, Oct, 10;104(41):e45073. https:\/\/doi.org\/10.1097\/MD.0000000000045073. PMID: 41088713; PMCID: PMC12517820.","DOI":"10.1097\/MD.0000000000045073"},{"key":"8473_CR17","doi-asserted-by":"publisher","first-page":"629666","DOI":"10.3389\/fonc.2021.629666","volume":"11","author":"S Dong","year":"2021","unstructured":"Dong S, Wang Z, Shen K, Chen X. Metabolic syndrome and breast cancer: prevalence, treatment response, and prognosis. Front Oncol. 2021, Mar, 25;11:629666. https:\/\/doi.org\/10.3389\/fonc.2021.629666. PMID: 33842335; PMCID: PMC8027241.","journal-title":"Front Oncol"},{"issue":"16","key":"8473_CR18","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1002\/cncr.33002","volume":"126","author":"K Pan","year":"2020","unstructured":"Pan K, Chlebowski RT, Mortimer JE, Gunther MJ, Rohan T, Vitolins MZ, et al. Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women\u2019s Health initiative. Cancer. 2020, Aug, 15;126(16):3638\u201347. https:\/\/doi.org\/10.1002\/cncr.33002. Epub 2020 Jun 12. Erratum in: Cancer.2020 Oct 20. doi: 10.1002\/cncr.33178. PMID: 32530506.","journal-title":"Cancer"},{"issue":"2","key":"8473_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/curroncol31020075","volume":"31","author":"L Szablewski","year":"2024","unstructured":"Szablewski L. Insulin resistance: the increased risk of Cancers. Curr Oncol. 2024, Feb, 13;31(2):998\u20131027. https:\/\/doi.org\/10.3390\/curroncol31020075. PMID: 38392069; PMCID: PMC10888119.","journal-title":"Curr Oncol"},{"issue":"34","key":"8473_CR20","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021, Sep, 7;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484 in: Eur Heart J. 2022 Nov 7; 43(42): 4468. doi: 10.1093\/eurheartj\/ehac458. PMID: 34458905.","journal-title":"Eur Heart J"},{"key":"8473_CR21","doi-asserted-by":"publisher","first-page":"133421","DOI":"10.1016\/j.ijcard.2025.133421","volume":"436","author":"S Wernhart","year":"2025","unstructured":"Wernhart S, Fiorentini C, Glowka S, Madl B, Grill S, Kiechle M, et al. Evaluating cardiovascular risk factors in breast cancer survivors: the role of echocardiography and cardiopulmonary exercise testing in the Munich cardio-oncology-exercise retrospective registry. Int J Cardiol. 2025, Oct, 1;436:133421. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133421. Epub 2025 May 25. Erratum in: Int J Cardiol. 2025 Nov 1; 438: 133472. doi: 10.1016\/j.ijcard.2025.133472. PMID: 40425074.","journal-title":"Int J Cardiol"},{"issue":"13","key":"8473_CR22","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.3390\/cancers17132198","volume":"17","author":"K Keramida","year":"2025","unstructured":"Keramida K, Constantinidou A, Tsekoura D, Kampouroglou E, Aidarinis C, Saloustros E, et al. Investigators cardiocare consortium. Cardiotoxicity in elderly breast cancer patients. Cancers (Basel). 2025, Jun, 30;17(13):2198. https:\/\/doi.org\/10.3390\/cancers17132198. PMID: 40647496; PMCID: PMC12249219.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"8473_CR23","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/ejhf.1985","volume":"22","author":"JL Zamorano","year":"2020","unstructured":"Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020, Dec;22(12):2290\u2013309. https:\/\/doi.org\/10.1002\/ejhf.1985. Epub 2020 Oct 2. PMID: 32809231; PMCID: PMC8278961.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"8473_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66(1):255\u201370. https:\/\/doi.org\/10.1146\/annurev-med-051013-110046. Epub 2014 Oct 17. PMID: 25341005.","journal-title":"Annu. Rev. Med"},{"issue":"12","key":"8473_CR25","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","volume":"65","author":"E Marilly","year":"2022","unstructured":"Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022, Dec;65(12):2000\u201310. https:\/\/doi.org\/10.1007\/s00125-022-05773-8. Epub 2022 Aug 4. PMID: 35925319.","journal-title":"Diabetologia"},{"issue":"6","key":"8473_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti AW, Patel R, Dani SS, Khadke S, Makwana B, Lessey C, et al. SGLT2i and Primary prevention of cancer therapy\u2013related cardiac dysfunction in patients with diabetes. JACC: CardioOncology. 2024, Sep, 22;6(6):863\u201375. https:\/\/doi.org\/10.1016\/j.jaccao.2024.08.001. PMID: 39801650; PMCID: PMC11711834.","journal-title":"JACC: CardioOncology"},{"issue":"8","key":"8473_CR27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/ph18081118","volume":"18","author":"M Suki","year":"2025","unstructured":"Suki M, Imam A, Amer J, Milgrom Y, Massarwa M, Hazou W, et al. SGLT2 inhibitors in MASLD (Metabolic dysfunction-associated steatotic liver disease) associated with sustained hepatic benefits, besides the cardiometabolic. Pharmaceuticals (Basel). 2025, Jul, 26;18(8):1118. https:\/\/doi.org\/10.3390\/ph18081118. PMID: 40872510; PMCID: PMC12389333.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"8473_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V. State-of-the-Art-review: mechanisms of Action of SGLT2 inhibitors and clinical Implications. Am J Hypertens. 2024, Oct, 14;37(11):841\u201352. https:\/\/doi.org\/10.1093\/ajh\/hpae092. PMID: 39017631; PMCID: PMC11471837.","journal-title":"Am J Hypertens"},{"issue":"37","key":"8473_CR29","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","volume":"44","author":"AK Pandey","year":"2023","unstructured":"Pandey AK, Bhatt DL, Pandey A, Marx N, Cosentino F, Pandey A, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023, Oct, 1;44(37):3640\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehad389. PMID: 37674356.","journal-title":"Eur Heart J"},{"issue":"4","key":"8473_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1536\/ihj.20-764","volume":"62","author":"M Nakagaito","year":"2021","unstructured":"Nakagaito M, Imamura T, Joho S, Ushijima R, Nakamura M, Kinugawa K. Relationship between HbA1c level and effectiveness of SGLT2 inhibitors in Decompensated Heart failure patients with type 2 diabetes mellitus. Int Heart J. 2021, Jul, 30;62(4):843\u201349. https:\/\/doi.org\/10.1536\/ihj.20-764. Epub 2021 Jul 17. PMID: 34276009.","journal-title":"Int Heart J"},{"key":"8473_CR31","doi-asserted-by":"publisher","first-page":"117090","DOI":"10.1016\/j.lfs.2019.117090","volume":"240","author":"H Yaribeygi","year":"2020","unstructured":"Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review. Life Sci. 2020, Jan, 1;240:117090. https:\/\/doi.org\/10.1016\/j.lfs.2019.117090. Epub 2019 Nov 22. PMID: 31765648.","journal-title":"Life Sci"},{"issue":"5","key":"8473_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1507\/endocrj.EJ19-0445","volume":"67","author":"A So","year":"2020","unstructured":"So A, Sakaguchi K, Okada Y, Morita Y, Yamada T, Miura H, et al. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor. Endocr J. 2020, May, 28;67(5):501\u201307. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0445. Epub 2020 Feb 6. PMID: 32023587.","journal-title":"Endocr J"},{"issue":"1","key":"8473_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12020-023-03652-9","volume":"84","author":"J Lin","year":"2024","unstructured":"Lin J, Zhan L, Chen Z, Lin X, Zhu R. The effect of SGLT2i on the GH\/IGF1 axis in newly diagnosed male T2D patients \u2013 a prospective, randomized case\u2013control study. Endocrine. 2024, Apr;84(1):203\u201312. https:\/\/doi.org\/10.1007\/s12020-023-03652-9. Epub 2024 Jan 2. PMID: 38168834.","journal-title":"Endocrine"},{"issue":"1","key":"8473_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00280-025-04791-8","volume":"95","author":"H Salah","year":"2025","unstructured":"Salah H, Rabea H, Sheemy MS, Rabie AI, Moustafa HAM, Elberry AA, et al. Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial. Cancer Chemother Pharmacol. 2025, Jun, 28;95(1):64. https:\/\/doi.org\/10.1007\/s00280-025-04791-8. PMID: 40579605.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"8473_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11883-025-01364-1","volume":"27","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Han L, Wang Y, Wang M. The role of the PI3K\/Akt\/mTOR pathway in atherosclerosis: mechanisms, therapeutic potential, and emerging targeted treatments. Curr Atheroscler Rep. 2025, Nov, 15;27(1):115. https:\/\/doi.org\/10.1007\/s11883-025-01364-1. PMID: 41240276.","journal-title":"Curr Atheroscler Rep"},{"issue":"20","key":"8473_CR36","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.3390\/ijms242015078","volume":"24","author":"S Saha","year":"2023","unstructured":"Saha S, Fang X, Green CD, Das A. mTORC1 and SGLT2 inhibitors\u2014A therapeutic perspective for diabetic cardiomyopathy. IJMS. 2023, Oct, 11;24(20):15078. https:\/\/doi.org\/10.3390\/ijms242015078. PMID: 37894760; PMCID: PMC10606418.","journal-title":"IJMS"},{"issue":"5","key":"8473_CR37","doi-asserted-by":"publisher","first-page":"167805","DOI":"10.1016\/j.bbadis.2025.167805","volume":"1871","author":"H Rao","year":"2025","unstructured":"Rao H, An X, Qu X, Yu J, Xie J, Ke J, et al. SGLT2i delays c-myc-induced HCC progression via targeting mTOR. Biochim Et Biophys Acta (BBA) - Mol Basis Disease. 2025, Jun;1871(5):167805. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167805. Epub 2025 Mar 18. PMID: 40113049.","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Disease"},{"issue":"1","key":"8473_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12933-024-02539-x","volume":"23","author":"C Morciano","year":"2024","unstructured":"Morciano C, Gugliandolo S, Capece U, Di Giuseppe G, Mezza T, Ciccarelli G, et al. SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives. Cardiovasc Diabetol. 2024, Dec, 19;23(1):449. https:\/\/doi.org\/10.1186\/s12933-024-02539-x. PMID: 39702365; PMCID: PMC11660748.","journal-title":"Cardiovasc Diabetol"},{"key":"8473_CR39","doi-asserted-by":"publisher","first-page":"112320","DOI":"10.1016\/j.mce.2024.112320","volume":"592","author":"J Qu","year":"2024","unstructured":"Qu J, Tian L, Zhang M, Sun B, Chen L. SGLT2 inhibitor canagliflozin reduces visceral adipose tissue in db\/db mice by modulating AMPK\/KLF4 signaling and regulating mitochondrial dynamics to induce browning. Mol Cellular Endocrinol. 2024, Oct, 1;592:112320. https:\/\/doi.org\/10.1016\/j.mce.2024.112320. Epub 2024 Jul 3. PMID: 38964727.","journal-title":"Mol Cellular Endocrinol"},{"issue":"5","key":"8473_CR40","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.3390\/ijms24054405","volume":"24","author":"Z Szekeres","year":"2023","unstructured":"Szekeres Z, Sandor B, Bognar Z, Ramadan FHJ, Palfi A, Bodis B, et al. Clinical study of metabolic parameters, leptin and the SGLT2 inhibitor empagliflozin among patients with obesity and type 2 diabetes. IJMS. 2023, Feb, 23;24(5):4405. https:\/\/doi.org\/10.3390\/ijms24054405. PMID: 36901837; PMCID: PMC10002958.","journal-title":"IJMS"},{"issue":"1","key":"8473_CR41","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020, May, 1;11(1):2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6. PMID: 32358544; PMCID: PMC7195385.","journal-title":"Nat Commun"},{"key":"8473_CR42","doi-asserted-by":"publisher","unstructured":"Safaie N, Masoumi S, Alizadeh S, Mirzajanzadeh P, Nejabati HR, Hajiabbasi M, et al. SGLT2 inhibitors and AMPK: the road to cellular housekeeping? Cell Biochem Function. 2024, Jan;42(1):e3922. https:\/\/doi.org\/10.1002\/cbf.3922. PMID: 38269506.","DOI":"10.1002\/cbf.3922"},{"issue":"4","key":"8473_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3803\/EnM.2024.2223","volume":"40","author":"SW Lee","year":"2025","unstructured":"Lee SW, Park H, Lee M, Lee H, Kang ES. Sodium-glucose cotransporter-2 inhibitor enhances hepatic gluconeogenesis and reduces lipid accumulation via AMPK-SIRT1 activation and autophagy induction. Endocrinol Metab (Seoul). 2025, Aug;40(4):583\u201397. https:\/\/doi.org\/10.3803\/EnM.2024.2223. Epub 2025 May 12. PMID: 40350800; PMCID: PMC12409166.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"8473_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","volume":"6","author":"MS Dabour","year":"2024","unstructured":"Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-Art review. JACC: CardioOncology. 2024, Mar, 12;6(2):159\u201382. https:\/\/doi.org\/10.1016\/j.jaccao.2024.01.007. PMID: 38774006; PMCID: PMC11103046.","journal-title":"JACC: CardioOncology"},{"issue":"23","key":"8473_CR45","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3390\/healthcare12232464","volume":"12","author":"R Brata","year":"2024","unstructured":"Brata R, Pascalau AV, Fratila O, Paul I, Muresan MM, Camarasan A, et al. Hemodynamic effects of SGLT2 inhibitors in patients with and without diabetes mellitus\u2014A narrative review. Healthcare (Basel). 2024, Dec, 6;12(23):2464. https:\/\/doi.org\/10.3390\/healthcare12232464. PMID: 39685086; PMCID: PMC11641081.","journal-title":"Healthcare (Basel)"},{"key":"8473_CR46","doi-asserted-by":"publisher","unstructured":"Shaaban A, Petersen A, Beckwith H, Florea N, Potter DA, Yee D, et al. Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time. Res Sq [Prepr]. 2023, Apr, 3;rs.3.rs-2758909. https:\/\/doi.org\/10.21203\/rs.3.rs-2758909\/v1. Update in: Cardiooncology. 2024 May 1; 10(1):27. doi: 10.1186\/s40959-024-00227-z. PMID: 37066265; PMCID: PMC10104271.","DOI":"10.21203\/rs.3.rs-2758909\/v1"},{"issue":"16","key":"8473_CR47","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","volume":"136","author":"M Packer","year":"2017","unstructured":"Packer M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of Heart failure. Circulation. 2017, Oct, 17;136(16):1548\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030418. PMID: 29038209.","journal-title":"Circulation"},{"key":"8473_CR48","doi-asserted-by":"publisher","unstructured":"Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, et al. A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol-Renal Physiol. 2020, Oct, 1;319(4):F712\u201328. https:\/\/doi.org\/10.1152\/ajprenal.00264.2020. Epub 2020 Sep 7. PMID: 32893663; PMCID: PMC7642886.","DOI":"10.1152\/ajprenal.00264.2020"},{"issue":"3","key":"8473_CR49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018, Mar;61(3):722\u201326. https:\/\/doi.org\/10.1007\/s00125-017-4509-7. Epub 2017 Dec 2. PMID: 29197997; PMCID: PMC6448958.","journal-title":"Diabetologia"},{"issue":"5","key":"8473_CR50","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","volume":"119","author":"S Chen","year":"2024","unstructured":"Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, et al. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Res Cardiol. 2024, Oct;119(5):751\u201372. https:\/\/doi.org\/10.1007\/s00395-024-01067-9. Epub 2024 Jul 24. PMID: 39046464; PMCID: PMC11461573.","journal-title":"Basic Res Cardiol"},{"issue":"14","key":"8473_CR51","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","volume":"117","author":"YJ Chung","year":"2021","unstructured":"Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. 2021, Dec, 17;117(14):2794\u2013806. https:\/\/doi.org\/10.1093\/cvr\/cvaa323. PMID: 33135077; PMCID: PMC8683707.","journal-title":"Cardiovasc Res"},{"issue":"14","key":"8473_CR52","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1093\/cvr\/cvab129","volume":"117","author":"CJ Zuurbier","year":"2021","unstructured":"Zuurbier CJ, Baartscheer A, Schumacher CA, Fiolet JWT, Coronel R. Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: persistent inhibition under various experimental conditions. Cardiovasc Res. 2021, Dec, 17;117(14):2699\u2013701. https:\/\/doi.org\/10.1093\/cvr\/cvab129. PMID: 33792689; PMCID: PMC8683702.","journal-title":"Cardiovasc Res"},{"key":"8473_CR53","doi-asserted-by":"publisher","unstructured":"Osataphan S, Macchi C, Singhal G, Chimene-Weiss J, Sales V, Kozuka C, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight. 2019, Mar, 7;4(5):e123130. https:\/\/doi.org\/10.1172\/jci.insight.123130. PMID: 30843877; PMCID: PMC6483601.","DOI":"10.1172\/jci.insight.123130"},{"key":"8473_CR54","doi-asserted-by":"publisher","unstructured":"Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and cardiovascular disease: 2025 ACC Scientific statement: a report of the American college of Cardiology. J Am Coll Cardiol. 2025, Sep;29:S0735\u20131097(25)07555\u20132. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.047. Epub ahead of print. PMID: 41020749.","DOI":"10.1016\/j.jacc.2025.08.047"},{"issue":"7","key":"8473_CR55","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3390\/ijms26073071","volume":"26","author":"S Cacciatore","year":"2025","unstructured":"Cacciatore S, Andaloro S, Bernardi M, Oterino Manzanas A, Spadafora L, Figliozzi S, et al. Chronic inflammatory Diseases and cardiovascular risk: current insights and future strategies for optimal management. IJMS. 2025, Mar, 27;26(7):3071. https:\/\/doi.org\/10.3390\/ijms26073071. PMID: 40243756; PMCID: PMC11989023.","journal-title":"IJMS"},{"key":"8473_CR56","doi-asserted-by":"publisher","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","volume":"111","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, et al. The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents. Int Immunopharmacol. 2022, Oct;111:109080. https:\/\/doi.org\/10.1016\/j.intimp.2022.109080. Epub 2022 Jul 28. PMID: 35908505.","journal-title":"Int Immunopharmacol"},{"key":"8473_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000548905","volume":"7","author":"HJ Li","year":"2025","unstructured":"Li HJ, Zhang LG, Wang YX, Liu S, Liu JY. The effect of sodium-dependent glucose transporter 2 inhibitors on cardiac structural and Functional indicators and Biochemical markers in older adults with hypertension and pre-Heart failure. Cardiology. 2025, Nov;7:1\u20138. https:\/\/doi.org\/10.1159\/000548905. Epub ahead of print. PMID: 41201974.","journal-title":"Cardiology"},{"issue":"5","key":"8473_CR58","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/antiox14050612","volume":"14","author":"V Quagliariello","year":"2025","unstructured":"Quagliariello V, Di Mauro A, Ferrara G, Bruzzese F, Palma G, Luciano A, et al. Cardio\u2013renal and systemic effects of SGLT2i Dapagliflozin on short-term anthracycline and HER-2-Blocking agent therapy-induced cardiotoxicity. Antioxid (Basel). 2025, May, 20;14(5):612. https:\/\/doi.org\/10.3390\/antiox14050612. PMID: 40427493; PMCID: PMC12108597.","journal-title":"Antioxid (Basel)"},{"issue":"1","key":"8473_CR59","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021, Jul, 23;20(1):150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y. PMID: 34301253; PMCID: PMC8305868.","journal-title":"Cardiovasc Diabetol"},{"issue":"23","key":"8473_CR60","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.3390\/cancers14235811","volume":"14","author":"M Dutka","year":"2022","unstructured":"Dutka M, Bobi\u0144ski R, Francuz T, Garczorz W, Zimmer K, Ilczak T, et al. SGLT-2 inhibitors in cancer treatment\u2014mechanisms of action and emerging new perspectives. Cancers (Basel). 2022, Nov, 25;14(23):5811. https:\/\/doi.org\/10.3390\/cancers14235811. PMID: 36497303; PMCID: PMC9738342.","journal-title":"Cancers (Basel)"},{"key":"8473_CR61","doi-asserted-by":"publisher","first-page":"110821","DOI":"10.1016\/j.biopha.2020.110821","volume":"132","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed Pharmacother. 2020, Dec;132:110821. https:\/\/doi.org\/10.1016\/j.biopha.2020.110821. Epub 2020 Oct 14. PMID: 33068934.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"8473_CR62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-025-04788-3","volume":"95","author":"W Dong","year":"2025","unstructured":"Dong W, Wang Y, Fan S. Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin. Cancer Chemother Pharmacol. 2025, Jun, 26;95(1):63. https:\/\/doi.org\/10.1007\/s00280-025-04788-3. PMID: 40569464.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"8473_CR63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40959-025-00368-9","volume":"11","author":"A Greco","year":"2025","unstructured":"Greco A, Quagliariello V, Rizzo G, Tedeschi A, Schirinzi S, Turco A, et al. SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +\/- trastuzumab: rationale and design of the multicenter PROTECT trial. Cardio-Oncology. 2025, Sep, 1;11(1):79. https:\/\/doi.org\/10.1186\/s40959-025-00368-9. PMID: 40890873; PMCID: PMC12400668.","journal-title":"Cardio-Oncology"},{"issue":"21","key":"8473_CR64","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. DAPA-HF trial committees and Investigators. Dapagliflozin in patients with Heart failure and reduced ejection fraction. N Engl J Med. 2019, Nov, 21;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303. Epub 2019 Sep 19. PMID: 31535829.","journal-title":"N Engl J Med"},{"issue":"1","key":"8473_CR65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40959-024-00260-y","volume":"10","author":"AJ Daniele","year":"2024","unstructured":"Daniele AJ, Gregorietti V, Costa D, L\u00f3pez \u2013 Fern\u00e1ndez T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD \u2013 PILOT trial. Cardio-Oncology. 2024, Sep, 5;10(1):58. https:\/\/doi.org\/10.1186\/s40959-024-00260-y. PMID: 39237985; PMCID: PMC11375926.","journal-title":"Cardio-Oncology"},{"issue":"15","key":"8473_CR66","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in Heart failure. N Engl J Med. 2020, Oct, 8;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190. Epub 2020 Aug 28. PMID: 32865377.","journal-title":"N Engl J Med"},{"issue":"16","key":"8473_CR67","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021, Oct, 14;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189.","journal-title":"N Engl J Med"},{"issue":"5","key":"8473_CR68","doi-asserted-by":"publisher","first-page":"817","DOI":"10.32604\/or.2024.048988","volume":"32","author":"S Karim","year":"2024","unstructured":"Karim S, Alghanmi AN, Jamal M, Alkreathy H, Jamal A, Alkhatabi HA, et al. A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells. OR. 2024, Apr, 23;32(5):817\u201330. https:\/\/doi.org\/10.32604\/or.2024.048988. PMID: 38686050; PMCID: PMC11055986.","journal-title":"OR"},{"issue":"1","key":"8473_CR69","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1507\/endocrj.EJ19-0428","volume":"67","author":"S Komatsu","year":"2020","unstructured":"Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J. 2020, Jan, 28;67(1):99\u2013106. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0428. Epub 2019 Nov 27. PMID: 31776304.","journal-title":"Endocr J"},{"key":"8473_CR70","doi-asserted-by":"publisher","first-page":"175883592513782","DOI":"10.1177\/17588359251378245","volume":"17","author":"YS Liu","year":"2025","unstructured":"Liu YS, Barner JC, Lawson KA, Liu Y, Park C. Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and\/or trastuzumab-based treatment. Ther Adv Med Oncol. 2025, Sep, 23;17:17588359251378245. https:\/\/doi.org\/10.1177\/17588359251378245. PMID: 41018041; PMCID: PMC12461033.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"8473_CR71","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/eurjpc\/zwaf026","volume":"33","author":"U Bhalraam","year":"2026","unstructured":"Bhalraam U, Veerni RB, Paddock S, Meng J, Piepoli M, L\u00f3pez-Fern\u00e1ndez T, et al. Impact of sodium\u2013glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur J Prev Cardiol. 2026, Mar;33(2):214\u201326. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf026. Epub ahead of print. PMID: 40044419.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"8473_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40959-025-00343-4","volume":"11","author":"T Reshadmanesh","year":"2025","unstructured":"Reshadmanesh T, Mohebi R, Behnoush AH, Reshadmanesh A, Khalaji A, Norouzi M, et al. The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis. Cardio-Oncology. 2025, May, 27;11(1):50. https:\/\/doi.org\/10.1186\/s40959-025-00343-4. PMID: 40426171; PMCID: PMC12107967.","journal-title":"Cardio-Oncology"},{"issue":"7\u20138","key":"8473_CR73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14796678.2024.2363673","volume":"20","author":"S Mohsin","year":"2024","unstructured":"Mohsin S, Hasan M, Sheikh ZM, Mustafa F, Tegeltija V, Kumar S, et al. Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients. Future Cardiol. 2024;20(7\u20138):395\u2013407. https:\/\/doi.org\/10.1080\/14796678.2024.2363673. Epub 2024 Jul 4. PMID: 38962942; PMCID: PMC11457630.","journal-title":"Future Cardiol"},{"issue":"1","key":"8473_CR74","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13098-025-01898-z","volume":"17","author":"H Hajishah","year":"2025","unstructured":"Hajishah H, Mazloom P, Salehi A, Kazemi D, Samiee R, Majlesi H, et al. Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025, Aug, 7;17(1):321. https:\/\/doi.org\/10.1186\/s13098-025-01898-z. PMID: 40770742; PMCID: PMC12330067.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"8473_CR75","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ehjcvp\/pvaf028","volume":"11","author":"G Novo","year":"2025","unstructured":"Novo G, Madaudo C, Cannat\u00e0 A, Ameri P, Di Lisi D, Bromage DI, et al. Effects of sodium\u2013glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis. Eur Heart J - Cardiovasc Pharmacother. 2025, Jul, 7;11(4):343\u201352. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf028. PMID: 40274419; PMCID: PMC12231130.","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"issue":"1","key":"8473_CR76","doi-asserted-by":"publisher","first-page":"2400797","DOI":"10.1080\/20565623.2024.2400797","volume":"10","author":"MI Obaid","year":"2024","unstructured":"Obaid MI, Shahzad MS, Latif F, Khan MH, Akram M, Mehdi Rizvi SA, et al. Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis. Future Sci OA. 2024, Dec, 31;10(1):2400797. https:\/\/doi.org\/10.1080\/20565623.2024.2400797. Epub 2024 Sep 30. PMID: 39344829; PMCID: PMC11444652.","journal-title":"Future Sci OA"},{"key":"8473_CR77","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3332\/ecancer.2025.1844","volume":"19","author":"C Wannaphut","year":"2025","unstructured":"Wannaphut C, Wattanachayakul P, Saowapa S, Ponvilawan B, Tanariyakul M, Kewcharoen J, et al. Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis. Ecancer J. 2025, Feb, 11;19:1844. https:\/\/doi.org\/10.3332\/ecancer.2025.1844. PMID: 40259909; PMCID: PMC12010125.","journal-title":"Ecancer J"},{"key":"8473_CR78","doi-asserted-by":"publisher","first-page":"176803","DOI":"10.1016\/j.ejphar.2024.176803","volume":"978","author":"Y Naeimzadeh","year":"2024","unstructured":"Naeimzadeh Y, Tajbakhsh A, Nemati M, Fallahi J. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies. Eur J Pharmacol. 2024, Sep, 5;978:176803. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176803. Epub 2024 Jun 29. PMID: 38950839.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"8473_CR79","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1186\/s12885-025-14304-8","volume":"25","author":"MA Karimi","year":"2025","unstructured":"Karimi MA, Khadem R, Haraj A, Farahani MA, Charehsaz Avari Firouzeh P, Azizinezhad A, et al. The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2025, Jun, 3;25(1):991. https:\/\/doi.org\/10.1186\/s12885-025-14304-8. PMID: 40461957; PMCID: PMC12135325.","journal-title":"BMC Cancer"},{"issue":"1","key":"8473_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4093\/dmj.2025.0964","volume":"50","author":"YK Cho","year":"2026","unstructured":"Cho YK, Jung CH. Sodium-glucose cotransporter 2 inhibitors as emerging anticancer agents. Diabetes Metab J. 2026, Jan;50(1):1\u201318. https:\/\/doi.org\/10.4093\/dmj.2025.0964. Epub 2026 Jan 1. PMID: 41531286.","journal-title":"Diabetes Metab J"},{"issue":"10","key":"8473_CR81","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","volume":"47","author":"B Xu","year":"2024","unstructured":"Xu B, Kang B, Li S, Fan S, Zhou J. Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis. J Endocrinol Invest. 2024, Oct;47(10):2421\u201336. https:\/\/doi.org\/10.1007\/s40618-024-02351-0. Epub 2024 Mar 26. PMID: 38530620.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"8473_CR82","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jcm15010378","volume":"15","author":"OM Bodea","year":"2026","unstructured":"Bodea OM, Serban S, Craciun ML, Mateescu DM, Florescu E, Muresan CO, et al. Effects of SGLT2 inhibitors on clinical outcomes, Symptoms, Functional Capacity, and cardiac remodeling in Heart failure: a Comprehensive systematic review and Multidomain meta-analysis of randomized trials. JCM. 2026, Jan, 4;15(1):378. https:\/\/doi.org\/10.3390\/jcm15010378. PMID: 41517628; PMCID: PMC12787172.","journal-title":"JCM"},{"issue":"2","key":"8473_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/eurjpc\/zwaf146","volume":"33","author":"J Cautela","year":"2026","unstructured":"Cautela J, Alexandre J. SGLT2 inhibitors in cancer patients: a paradigm shift in cardio-oncology? Eur J Prev Cardiol. 2026, Feb, 3;33(2):227\u201328. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf146. PMID: 40101149.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"8473_CR84","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jaccao.2024.10.005","volume":"6","author":"MS Dabour","year":"2024","unstructured":"Dabour MS, Blaes AH, Ramu B, Zordoky BN. SGLT2 inhibitors in mitigating cancer therapy-related cardiac dysfunction: expanding the evidence. JACC: CardioOncology. 2024, Dec, 17;6(6):876\u201378. https:\/\/doi.org\/10.1016\/j.jaccao.2024.10.005. PMID: 39801638; PMCID: PMC11711823.","journal-title":"JACC: CardioOncology"},{"issue":"8","key":"8473_CR85","doi-asserted-by":"publisher","first-page":"753313","DOI":"10.3389\/fcvm.2021.753313","volume":"8","author":"H Xiao","year":"2021","unstructured":"Xiao H, Wang X, Li S, Liu Y, Cui Y, Deng X. Advances in biomarkers for detecting early cancer treatment-related cardiac dysfunction. Front. Cardiovasc. Med. 2021, Nov;8(8):753313. https:\/\/doi.org\/10.3389\/fcvm.2021.753313. PMID: 34859069; PMCID: PMC8631401.","journal-title":"Front. Cardiovasc. Med"},{"issue":"12","key":"8473_CR86","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jcmg.2024.07.018","volume":"17","author":"C Collet","year":"2024","unstructured":"Collet C, Sakai K, Mizukami T, Ohashi H, Bouisset F, Caglioni S, et al. Vascular remodeling in coronary microvascular dysfunction. JACC Cardiovasc Imag. 2024, Dec;17(12):1463\u201376. https:\/\/doi.org\/10.1016\/j.jcmg.2024.07.018. Epub 2024 Sep 11. PMID: 39269414.","journal-title":"JACC Cardiovasc Imag"},{"issue":"4","key":"8473_CR87","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/fca-2016-0012","volume":"12","author":"OY Hung","year":"2016","unstructured":"Hung OY, Lee SK, Eshtehardi P, Samady H. Novel biomarkers of coronary microvascular disease. Future Cardiol. 2016, Jul;12(4):497\u2013509. https:\/\/doi.org\/10.2217\/fca-2016-0012. Epub 2016 Jun 13. PMID: 27291585; PMCID: PMC5941701.","journal-title":"Future Cardiol"},{"issue":"1","key":"8473_CR88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","volume":"12","author":"V Avula","year":"2024","unstructured":"Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy\u2013related cardiac dysfunction. JACC Heart Fail. 2024, Jan;12(1):67\u201378. https:\/\/doi.org\/10.1016\/j.jchf.2023.08.026. Epub 2023 Oct 25. PMID: 37897456.","journal-title":"JACC Heart Fail"},{"issue":"17","key":"8473_CR89","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Pharmacovigilance study team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. JNCI J The Natl Cancer Inst. 2012, Sep, 5;104(17):1293\u2013305. https:\/\/doi.org\/10.1093\/jnci\/djs317. PMID: 22949432; PMCID: PMC3433392.","journal-title":"JNCI J The Natl Cancer Inst"},{"issue":"6","key":"8473_CR90","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","volume":"109","author":"CH Chiang","year":"2023","unstructured":"Chiang CH, Chiang CH, Chiang CH, Ma KS-K, Peng CY, Hsia YP, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023, Feb, 23;109(6):470\u201377. https:\/\/doi.org\/10.1136\/heartjnl-2022-321545. PMID: 36351793; PMCID: PMC10037540.","journal-title":"Heart"},{"issue":"8","key":"8473_CR91","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/clinem\/dgad225","volume":"108","author":"AR Cappola","year":"2023","unstructured":"Cappola AR, Auchus RJ, El-Hajj Fuleihan G, Handelsman DJ, Kalyani RR, McClung M, et al. Hormones and aging: an endocrine society scientific statement. J Clin Endocr Metab. 2023, Jul, 14;108(8):1835\u201374. https:\/\/doi.org\/10.1210\/clinem\/dgad225. PMID: 37326526; PMCID: PMC11491666.","journal-title":"J CLIN ENDOCR Metab"},{"issue":"7","key":"8473_CR92","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/jcdd9070225","volume":"9","author":"D Kurczy\u0144ski","year":"2022","unstructured":"Kurczy\u0144ski D, Hudzik B, Jagosz M, Zabierowski J, Nowak J, Tomasik A, et al. Sodium-glucose cotransporter-2 inhibitors-from the treatment of diabetes to therapy of Chronic Heart failure. JCDD. 2022, Jul, 14;9(7):225. https:\/\/doi.org\/10.3390\/jcdd9070225. PMID: 35877587; PMCID: PMC9325125.","journal-title":"JCDD"},{"issue":"11","key":"8473_CR93","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41594-022-00856-x","volume":"29","author":"L Garcia-Martinez","year":"2022","unstructured":"Garcia-Martinez L, Adams AM, Chan HL, Nakata Y, Weich N, Stransky S, et al. Endocrine resistance and breast cancer plasticity are controlled by CoREST. Nat Struct Mol Biol. 2022, Nov;29(11):1122\u201335. https:\/\/doi.org\/10.1038\/s41594-022-00856-x. Epub 2022 Nov 7. PMID: 36344844; PMCID: PMC9707522.","journal-title":"Nat Struct Mol Biol"},{"key":"8473_CR94","doi-asserted-by":"publisher","unstructured":"Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer. 2005, Jul;12(Supplement_1):S61\u201373. https:\/\/doi.org\/10.1677\/erc.1.01018. PMID: 16113100.","DOI":"10.1677\/erc.1.01018"},{"issue":"1","key":"8473_CR95","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41392-025-02493-4","volume":"10","author":"H Zhang","year":"2025","unstructured":"Zhang H, Xiao X, Pan Z, Dokudovskaya S. mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics. Sig Transduct Target Ther. 2025, Dec, 30;10(1):428. https:\/\/doi.org\/10.1038\/s41392-025-02493-4. PMID: 41469379; PMCID: PMC12753737.","journal-title":"Sig Transduct Target Ther"},{"issue":"3","key":"8473_CR96","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/cen.14050","volume":"91","author":"D Zhang","year":"2019","unstructured":"Zhang D, Yang X, Li J, Yu J, Wu X. Effect of hyperinsulinaemia and insulin resistance on endocrine, metabolic and fertility outcomes in women with polycystic ovary syndrome undergoing ovulation induction. Clin Endocrinol (Oxford). 2019, Sep;91(3):440\u201348. https:\/\/doi.org\/10.1111\/cen.14050. Epub 2019 Jun 28. PMID: 31222771.","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"13","key":"8473_CR97","doi-asserted-by":"publisher","first-page":"897167","DOI":"10.3389\/fphar.2022.897167","volume":"13","author":"R Guo","year":"2022","unstructured":"Guo R, Wang P, Zheng X, Cui W, Shang J, Zhao Z. SGLT2 inhibitors suppress epithelial\u2013mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R\/PI3K pathway. Front Pharmacol. 2022, Sep;13(13):897167. https:\/\/doi.org\/10.3389\/fphar.2022.897167 in:Front Pharmacol.2022 Dec 22;13:1074294.doi 10.3389\/fphar.2022.1074294. PMID: 36225569; PMCID: PMC9550168.","journal-title":"Front Pharmacol"},{"issue":"1","key":"8473_CR98","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13058-016-0697-1","volume":"18","author":"C Leroy","year":"2016","unstructured":"Leroy C, Ramos P, Cornille K, Bonenfant D, Fritsch C, Voshol H, et al. Activation of IGF1R\/p110\u03b2\/AKT\/mTOR confers resistance to \u03b1-specific PI3K inhibition. Breast Cancer Res. 2016, Apr, 5;18(1):41. https:\/\/doi.org\/10.1186\/s13058-016-0697-1. PMID: 27048245; PMCID: PMC4820873.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"8473_CR99","doi-asserted-by":"publisher","first-page":"172","DOI":"10.37349\/etat.2022.00078","volume":"3","author":"A Skolariki","year":"2022","unstructured":"Skolariki A, D\u2019Costa J, Little M, Lord S. Role of PI3K\/Akt\/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration Targeted Anti-Tumor Ther. 2022;3(2):172\u201399. https:\/\/doi.org\/10.37349\/etat.2022.00078. Epub 2022 Apr 24. PMID: 36046843; PMCID: PMC9400772.","journal-title":"Exploration Targeted Anti-Tumor Ther"},{"issue":"4","key":"8473_CR100","doi-asserted-by":"publisher","first-page":"480","DOI":"10.37349\/etat.2022.00096","volume":"3","author":"D Musheyev","year":"2022","unstructured":"Musheyev D, Alayev A. Endocrine therapy resistance: what we know and future directions. Exploration Targeted Anti-Tumor Ther. 2022;3(4):480\u201396. https:\/\/doi.org\/10.37349\/etat.2022.00096. Epub 2022 Aug 31. PMID: 36071983; PMCID: PMC9446423.","journal-title":"Exploration Targeted Anti-Tumor Ther"},{"issue":"27","key":"8473_CR101","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1038\/onc.2015.414","volume":"35","author":"A Alayev","year":"2016","unstructured":"Alayev A, Salamon RS, Berger SM, Schwartz NS, Cuesta R, Snyder RB, et al. mTORC1 directly phosphorylates and activates ER\u03b1 upon estrogen stimulation. Oncogene. 2016, Jul, 7;35(27):3535\u201343. https:\/\/doi.org\/10.1038\/onc.2015.414. Epub 2015 Nov 2. PMID: 26522726; PMCID: PMC4853282.","journal-title":"Oncogene"},{"issue":"1","key":"8473_CR102","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Sig Transduct Target Ther. 2022, Jul, 6;7(1):216. https:\/\/doi.org\/10.1038\/s41392-022-01073-0. PMID: 35794109; PMCID: PMC9259665.","journal-title":"Sig Transduct Target Ther"},{"issue":"3","key":"8473_CR103","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/cancers17030466","volume":"17","author":"A Pandey","year":"2025","unstructured":"Pandey A, Alcaraz M Jr, Saggese P, Soto A, Gomez E, Jaldu S, et al. Exploring the role of SGLT2 inhibitors in cancer: mechanisms of Action and therapeutic Opportunities. Cancers (Basel). 2025, Jan, 30;17(3):466. https:\/\/doi.org\/10.3390\/cancers17030466. PMID: 39941833; PMCID: PMC11815934.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"8473_CR104","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.drudis.2016.05.012","volume":"21","author":"T De Marchi","year":"2016","unstructured":"De Marchi T, Foekens JA, Umar A, Martens JWM. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov. Today Today. 2016, Jul;21(7):1181\u201388. https:\/\/doi.org\/10.1016\/j.drudis.2016.05.012. Epub 2016 May 24. PMID: 27233379.","journal-title":"Drug Discov. Today Today"},{"issue":"3","key":"8473_CR105","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4172\/2329-6607.1000154","volume":"4","author":"Y Lipovka","year":"2015","unstructured":"Lipovka Y, Konhilas JP. AMP-Activated protein kinase signalling in cancer and cardiac hypertrophy. Cardiovasc Pharm Open Access. 2015, Aug;4(3):154. https:\/\/doi.org\/10.4172\/2329-6607.1000154. Epub 2015 Aug 31. PMID: 26798768; PMCID: PMC4718578.","journal-title":"Cardiovasc Pharm Open Access"},{"issue":"5","key":"8473_CR106","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.cpcardiol.2024.102524","volume":"49","author":"FR Alsereidi","year":"2024","unstructured":"Alsereidi FR, Khashim Z, Marzook H, Gupta A, Al-Rawi AM, Ramadan MM, et al. Targeting inflammatory signaling pathways with SGLT2 inhibitors: insights into cardiovascular health and cardiac cell improvement. Curr Probl Cardiol. 2024, May;49(5):102524. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102524. Epub 2024 Mar 16. PMID: 38492622.","journal-title":"Curr Probl Cardiol"},{"issue":"14","key":"8473_CR107","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1158\/1078-0432.CCR-20-0269","volume":"26","author":"RA Hampsch","year":"2020","unstructured":"Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, et al. AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells. Clin Cancer Res. 2020, Jul, 15;26(14):3707\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0269. Epub 2020 Apr 22. PMID: 32321715; PMCID: PMC7367755.","journal-title":"Clin Cancer Res"},{"key":"8473_CR108","doi-asserted-by":"publisher","unstructured":"Barone I, Caruso A, Gelsomino L, Giordano C, Bonofiglio D, Catalano S, et al. Obesity and endocrine therapy resistance in breast cancer: mechanistic insights and perspectives. Obes Rev. 2022, Feb;23(2):e13358. https:\/\/doi.org\/10.1111\/obr.13358. Epub 2021 Sep 24. PMID: 34559450; PMCID: PMC9285685.","DOI":"10.1111\/obr.13358"},{"key":"8473_CR109","doi-asserted-by":"publisher","unstructured":"Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol-Cell Physiol. 2021, Mar, 1;320(3):C375\u201391. https:\/\/doi.org\/10.1152\/ajpcell.00379.2020. Epub 2020 Dec 23. PMID: 33356944; PMCID: PMC8294624.","DOI":"10.1152\/ajpcell.00379.2020"},{"issue":"1","key":"8473_CR110","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12979-025-00545-5","volume":"22","author":"Y Song","year":"2025","unstructured":"Song Y, Xing H, Luo Y, Li B, Li Y, Dong Z. Adipose immune microenvironment: catalyst of age-related adipose tissue dysfunction. Immun Ageing. 2025, Nov, 21;22(1):53. https:\/\/doi.org\/10.1186\/s12979-025-00545-5. PMID: 41272743; PMCID: PMC12639662.","journal-title":"Immun Ageing"},{"issue":"5","key":"8473_CR111","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/biomedicines13051098","volume":"13","author":"M Mazurkiewicz","year":"2025","unstructured":"Mazurkiewicz M, Bodnar P, Blachut D, Chwalba T, Wagner W, Barczyk E, et al. Adipokines and adipose tissue: the role and use of sodium-glucose Co-transporter-2 (SGLT-2) inhibitors in patients with diabetes or Heart failure. Biomedicines. 2025, Apr, 30;13(5):1098. https:\/\/doi.org\/10.3390\/biomedicines13051098. PMID: 40426925; PMCID: PMC12108695.","journal-title":"Biomedicines"},{"issue":"12","key":"8473_CR112","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1007\/s11010-025-05379-9","volume":"480","author":"Z Xu","year":"2025","unstructured":"Xu Z, Yang S, Tan Y, Zhang Q, Wang H, Tao J, et al. Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms\u2013a comprehensive review. Mol Cell Biochem. 2025, Dec;480(12):6039\u201375. https:\/\/doi.org\/10.1007\/s11010-025-05379-9. Epub 2025 Sep 10. PMID: 40928582; PMCID: PMC12594699.","journal-title":"Mol Cell Biochem"},{"key":"8473_CR113","doi-asserted-by":"publisher","unstructured":"Carleton N, Lee S, Li R, Zou J, Brown DD, Hooda J, et al. Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women. bioRxiv [Prepr]. 2024, Oct;21:2024.10.18.616978. https:\/\/doi.org\/10.1101\/2024.10.18.616978. PMID: 39484485; PMCID: PMC11526964.","DOI":"10.1101\/2024.10.18.616978"},{"issue":"3","key":"8473_CR114","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1210\/me.2011-1302","volume":"26","author":"SC Baumgarten","year":"2012","unstructured":"Baumgarten SC, Frasor FJ. Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol. 2012, Mar;26(3):360\u201371. https:\/\/doi.org\/10.1210\/me.2011-1302. Epub 2012 Feb 2. PMID: 22301780; PMCID: PMC3286192.","journal-title":"Mol Endocrinol"},{"issue":"1","key":"8473_CR115","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021, Jan;3(1):21\u201332. https:\/\/doi.org\/10.1038\/s42255-020-00317-z. Epub 2021 Jan 4. PMID: 33398194; PMCID: PMC8097259.","journal-title":"Nat Metab"},{"issue":"9","key":"8473_CR116","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","volume":"472","author":"EM Wright","year":"2020","unstructured":"Wright EM. SGLT2 and cancer. Pflugers Arch - Eur J Physiol. 2020, Sep;472(9):1407\u201314. https:\/\/doi.org\/10.1007\/s00424-020-02448-4. Epub 2020 Aug 20. Erratum in: Pflugers Arch. 2021 Nov; 473(11): 1807. doi: 10.1007\/s00424-021-02625-z. PMID: 32820343; PMCID: PMC7462911.","journal-title":"Pflugers Arch - Eur J Physiol"},{"issue":"1","key":"8473_CR117","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s12672-025-04046-1","volume":"16","author":"F Luc\u00e0","year":"2025","unstructured":"Luc\u00e0 F, Parrini I. SGLT2 inhibitors and their role in reducing mortality among cancer patients with type 2 diabetes undergoing immune checkpoint inhibitor therapy. Discov Oncol. 2025, Nov, 17;16(1):2109. https:\/\/doi.org\/10.1007\/s12672-025-04046-1. PMID: 41249742; PMCID: PMC12623602.","journal-title":"Discov Oncol"},{"key":"8473_CR118","doi-asserted-by":"publisher","unstructured":"Shi R, Zhan Y, Ma R, Ali S, Yao C, Chun TTS, et al. Sodium-glucose cotransporter 2 inhibitors for patients with prostate cancer undergoing hormone therapy. JAMA Oncol. 2026, Jan;12(3):e255869. https:\/\/doi.org\/10.1001\/jamaoncol.2025.5869. Epub ahead of print. PMID: 41505116; PMCID: PMC12784257.","DOI":"10.1001\/jamaoncol.2025.5869"},{"issue":"8","key":"8473_CR119","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.3390\/ijms27083597","volume":"27","author":"V Quagliariello","year":"2026","unstructured":"Quagliariello V, Berretta M, Barbato M, Maurea F, Canale ML, Paccone A, et al. SGLT2 inhibitor Dapagliflozin attenuates cardiomyocyte injury and inflammation induced by PI3K\u03b1-selective inhibitor alpelisib and fulvestrant under hyperglycemia. IJMS. 2026, Apr, 17;27(8):3597. https:\/\/doi.org\/10.3390\/ijms27083597. PMID: 42074235; PMCID: PMC13116710.","journal-title":"IJMS"},{"issue":"10","key":"8473_CR120","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3390\/cancers17101653","volume":"17","author":"A Khan","year":"2025","unstructured":"Khan A, Sisodiya S, Aftab M, Tanwar P, Hussain S, Gupta V. Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: a Comprehensive review and meta-analysis. Cancers (Basel). 2025, May, 14;17(10):1653. https:\/\/doi.org\/10.3390\/cancers17101653. PMID: 40427153; PMCID: PMC12109706.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"8473_CR121","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","volume":"99","author":"O Saatci","year":"2021","unstructured":"Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med (Berl). 2021, Dec;99(12):1691\u2013710. https:\/\/doi.org\/10.1007\/s00109-021-02136-5. Epub 2021 Oct 8. PMID: 34623477; PMCID: PMC8611518.","journal-title":"J Mol Med (Berl)"},{"key":"8473_CR122","doi-asserted-by":"publisher","unstructured":"Hoong CWS, Chua MWJ. SGLT2 inhibitors as Calorie Restriction Mimetics: insights on Longevity pathways and age-related Diseases. Endocrinology. 2021, Aug, 1;162(8):bqab079. https:\/\/doi.org\/10.1210\/endocr\/bqab079. PMID: 33857309.","DOI":"10.1210\/endocr\/bqab079"},{"issue":"4","key":"8473_CR123","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11154-025-09958-5","volume":"26","author":"RM Ruggeri","year":"2025","unstructured":"Ruggeri RM, Grossrubatscher EM, Ciocca E, Hasballa I, Jaafar S, Oldani M, et al. Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions. Rev Endocr Metab Disord. 2025, Aug;26(4):575\u201392. https:\/\/doi.org\/10.1007\/s11154-025-09958-5. Epub 2025 Apr 2. PMID: 40175622; PMCID: PMC12316766.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"8473_CR124","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40959-024-00284-4","volume":"11","author":"C Simela","year":"2025","unstructured":"Simela C, Walker JM, Ghosh AK, Chen DH. SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights. Cardio-Oncology. 2025, Feb, 11;11(1):15. https:\/\/doi.org\/10.1186\/s40959-024-00284-4. PMID: 39934910; PMCID: PMC11818010.","journal-title":"Cardio-Oncology"},{"issue":"19","key":"8473_CR125","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3390\/cancers17193225","volume":"17","author":"S Saha","year":"2025","unstructured":"Saha S, Singh PK, Roy P, Vemuri V, Ratajczak MZ, Singh M, et al. Cancer-induced cardiac dysfunction: mechanisms, diagnostics, and emerging therapeutics in the era of onco-Cardiology. Cancers (Basel). 2025, Oct, 3;17(19):3225. https:\/\/doi.org\/10.3390\/cancers17193225. PMID: 41097751; PMCID: PMC12523736.","journal-title":"Cancers (Basel)"},{"key":"8473_CR126","doi-asserted-by":"publisher","unstructured":"Sultan A, Naeem MN, Javed N, Rehman M, Danial A. Euglycemic diabetic Ketoacidosis associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors: a case series and clinical reflections. Cureus. 2025, Nov, 8;17(11):e96393. https:\/\/doi.org\/10.7759\/cureus.96393. PMID: 41376763; PMCID: PMC12686196.","DOI":"10.7759\/cureus.96393"},{"issue":"10","key":"8473_CR127","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015, Oct;12(10):573\u201383. https:\/\/doi.org\/10.1038\/nrclinonc.2015.117. Epub 2015 Jun 30. PMID: 26122181; PMCID: PMC4911210.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08473-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08473-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08473-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:04:36Z","timestamp":1788782676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08473-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8473"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08473-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a narrative review and did not involve human participants or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1147"}}